RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP), (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announced that it has commenced the process to have the Company’s common shares quoted on the OTCQB® Market exchange in the United States. The Company’s U.S. legal counsel, Sheppard Mullin,
Richter and Hampton LLC will be acting as Principal American Liaison (“PAL”) in assisting the company through the listing application process. Pending due diligence and fulfilling various regulatory requirements, management believes the process should take no more than two months.
Expanding to the OTCQB® will provide existing shareholders with an additional trading platform to the Toronto Stock Exchange in addition to introducing the company to a broader range of institutional and retail investors in the U.S. Listing on the OTCQB® represents a first step in fulfilling the Company’s ambitions to list on a U.S. stock exchange, such as NASDAQ.